174ACTIVITIES
1ORGS REPRESENTED
56BILLS
Organizations represented
1Orgs whose LD-2 filings list Aiken as an active lobbyist, sorted by activity volume.
Bills they file on
56H.R. 126249 mentions
S. 52747 mentions
S. 109746 mentions
S. 109646 mentions
S. 93245 mentions
S. 227644 mentions
S. 4344 mentions
H.R. 648543 mentions
H.R. 326942 mentions
H.R. 167237 mentions
S. 86432 mentions
S. 52631 mentions
S. 109531 mentions
S. 104131 mentions
H.R. 616630 mentions
+ 41 more bills referenced in their activities
Topics in Filings
483Policy topics Aiken files on across all their LD-2 activities.
Medical Countermeasure Priority Review Voucher Reauthorization×146
CMMI: GLOBE and GUARD Models×112
Interagency Patent Coordination and Improvement Act×93
Preserve Access to Affordable Generics and Biosimilars Act×91
Prescription Pricing for the People Act×89
National Coverage Determination×87
Antimicrobial Resistance×86
International Pricing Policies×84
R&D Funding for Medical Countermeasures×79
Lowering Drug Costs for American Families Act×77
Development and Procurement×72
Pharmacy Benefit Manager Transparency Act×72
Show all 483 topics (+471 more) ▾
CMMI Authority×72
Funding for Strategic National Stockpile×71
Stop STALLING Act×71
Most Favored Nation Drug Pricing Proposals×71
Pandemic Preparedness×70
FY 2026 Appropriations for Agencies×68
Biodefense/Biomedical/Emergency Preparedness Research×68
FY 2026 Appropriations for Specific Issues×67
Centers for Disease Control and Prevention×67
Health Resources and Services Administration×67
HHS Office of Infectious Disease and HIV/AIDS Policy×65
Big Savings Act×58
Pediatric Priority Review Voucher×57
Maintaining Investments and New Innovation×56
Administration for Strategic Preparedness and Response×56
Biomedical Advanced Research and Development Authority×56
340B Rebate Rule×56
Development and Procurement Issues×54
Drug Supply Chain Management×52
Supply Chain Issues×52
Vaccines and Infectious Diseases×51
Clinical Trial Data in China×51
Drug Pricing×50
MCM PRV Reauthorization×43
Restrictions on Intellectual Property Rights×42
Food & Drug Administration×42
Data Privacy Working Group Draft×42
FY 2025 Appropriations×41
Vaccine Injury Compensation Program×40
Affordable Prescriptions for Patients Act×38
Risky Research Review Act×37
Quality & Distribution×36
Advanced Manufacturing×36
Drug Shortages×36
Supply Chain Integrity and Traceability×36
Patient Cost-Sharing and Implementation×36
Alternative Payment Arrangements for Gene Therapies×36
Drug Benefit Design×36
National Defense Authorization Act×36
Adult Immunization×36
Vaccine Safety net and Vaccine Infrastructure×36
Value of Vaccines and Vaccine Confidence×36
Pricing and Rebates×35
MCM Manufacturing & Capacity×35
Orphan Drug Tax Credit×35
Vaccine Injury Compensation Modernization×35
Average Manufacturer Price Calculations×34
Support of Patient Premiums and Cost-Sharing Obligations×34
Let Injured Americans Be Legally Empowered×34
Vaccine Access Improvement Act×34
Alternative Funding Programs×34
Biosimilar Red Tape Elimination Act×34
SAFE STEP Act×34
Funding for Women's Health Research×33
Medicare Drug Price Negotiation Act×33
Modernizing and Ensuring PBM Accountability×33
Value-based Contracting and Communications×32
Medicaid VBPs for Patients×32
FY 2026 Appropriations×31
Increasing Transparency in Generic Drug Application×31
Pandemic Preparedness -R&D Funding for Medical Countermeasures×30
Non-Opioid Analgesics Orphan Drug Issues×29
Biosecurity Modernization×29
Centers for Medicare and Medicaid×28
National Institutes of Health×28
Funding for Section 317×28
National Defense Authorization Act 2027×28
Biosimilars Competition×28
CMMI×28
Pediatric Priority Review Voucher Pandemic Preparedness×28
BIOSECURE Act×27
Bio COMPETES×27
Value-Based Purchasing×24
House GOP RFI on Supply Chain×22
Executive Order on Access to Affordable Life-Saving Medications×22
Strengthening Innovation in Medicare and Medicaid Act×22
China Biotechnology Regulations×21
Medication Affordability and Patient Integrity Act×21
Biosimilar Copay×21
Interchangeability and Pharmacy Substitution×21
Promising Pathway Act×21
Medicare Part B Physician-Administered Products×21
Maternal Immunization×21
Program Implementation & Oversight×21
Helping Startups Continue to Grow Act×21
American Innovation and Jobs Act×21
Mandating Exclusive Review of Individual Treatments×21
Advanced Research Projects Agency for Health×20
American Privacy Rights Act×20
CICP×20
PBM Reform×20
Coverage of Accelerated Approval Products×20
Patient Cost-Sharing and Smoothing×20
PROTECT 340B Act×20
Prescription Drug User Fee Act×20
TRIPS Waiver×19
Accelerated Approval Artificial Intelligence×19
COVID-19 Pricing Related Provisions×19
Countermeasures Injury Compensation Program×19
Vaccine Safety and Quality×19
VICP Loopholes×19
SUSTAIN 340B Act×19
Access to Innovative Treatments Act×19
One Big Beautiful Bill Act×19
Bayh-Dole Act×18
Drug Patenting×18
Section 101 Modernization×18
Genetic Resources, and Associated Traditional Knowledge×18
MCM PRV Program Reauthorization×18
WHO Pandemic Preparedness Accord Biosimilars×18
Reimbursement Cell & Gene Therapy×18
Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×18
Vaccine and Antimicrobial Resistance Product Development and Incentives×18
Medicaid Drug Rebate Program×18
Accredited Investor Definition Review Act×18
Equal Opportunity for All Investors Act×18
Expensing of R&D Expenditures×18
Countermeasure Injury Compensation Fund Amendment Act×18
CFIUS and Foreign Investment Drug Pricing×18
Pandemic Flu×18
Foreign Drug Data Protection Laws×18
Pharmacy Benefit Managers Artificial Intelligence×17
Treaty on Intellectual Property×17
ORPHAN Cures Act×17
State Strategic Stockpile Act×17
Accredited Investor Definition×17
Biosimilars Red Tape Elimination Act×17
Vaccine Access & Compensation×17
Influenza Planning & Response×17
Project Bioshield×17
FDA Hiring Flexibility×17
DRUG Act×17
FDA Modernization×17
Act 3.0 Medicaid×17
Innovation in Pediatric Drugs Act×17
Retaining Access and Restoring Exclusivity×17
Step Therapy×17
MCM R&D Incentives×17
Vaccine Quality Measure×17
Vaccine Safety×17
Section 232×17
Climate Issues & impact on the agriculture and food sectors×16
Diversity & Inclusion×16
Compounded Medicines×16
Fair Investment Opportunities for Professional Experts Act×16
Decentralized Clinical Trials Drug Evaluation and Review×16
Precision Medicine Initiative Reimbursement and Coverage of Innovative Products×16
Patenting of Biological Inventions×16
Disease X Act×16
Gain of function×16
SAFE Risky Research Act×16
Capital Formation Incentives×16
Reference Pricing in Drug Reimbursement×16
World Intellectual Property Office×16
Generic Drug Entry×16
Generic Drug Application Review Reforms×16
Incentives for Generic Entry Issues×16
Funding for Medical Countermeasures×16
Accelerated Approval Antimicrobial Resistance Artificial Intelligence×16
VICP/CICP Capital Formation Incentives×16
White House National Biodefense Strategy×15
Coverage and Reimbursement×15
Public Float Threshold Update Small Business Innovation Research×15
Tariffs Foreign Agricultural Biotechnology Laws and Regulations×15
Patent Tax/fees×15
Section 317 Immunization Program×15
Vaccine Injury Compensation Program 340B Drug Discount Program×15
Compounding Pharmacies×15
Contract Manufacturing Ecosystem in the United States×15
Access to Innovative Treatments×15
PASTEUR ACT×15
WHO Pandemic Preparedness Accord Pandemic Preparedness×15
VICP/CICP Antimicrobial Resistance Biodefense Research×15
Vaccines and Infectious Diseases 340B Drug Discount Program×15
Most Favored Nation in Medicaid×15
NSCEB Recommendations Opioid Crisis×15
Cameron's Law Pandemic Preparedness Research & Development Tax Credit Reforms×15
CMMI Models: GLOBE and GUARD×14
Compulsory Licensing×14
28 U.S.C. 1498×14
Patent and copyright cases Data Privacy×14
Patent Reform×14
PTAB Reform×14
Purple Book Draft×14
Consumer Data Privacy and Security Act×14
Diagnostics and Personalized Medicine Regulation and Oversight×14
PDUFA VII Implementation×14
PDUFA VIII Negotiations Drug Importation Drug Manufacturing×14
NSC/OSTP priorities×14
Nucleic acid synthesis security and biotechnology governance×14
Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products×14
VICP/CICP Biodefense Research×14
CDC Reform×14
FDA Hiring Staffing Drug Importation Drug Manufacturing×14
Tariffs Foreign Drug Data Protection Laws Medicaid×14
Capital Market Enhancements×14
INNOVATE Act×14
Small Business Innovation and Economic Security Act×14
Incentives for Domestics Manufacturing Orphan Drug Issues×14
R&D Payroll Credit Vaccines and Infectious Disease×14
China Synthetic Biotech×14
US-China IP Provisions United Nations World Trade Organization×14
Monoclonal Antibody Coverage and Utilization×13
Incentives for Sustainable Aviation Fuels×10
FDA Approvals×9
Guidance, & Regulations×9
WHO Pandemic Preparedness Accord×9
Farm Bill Reauthorization×8
Biomass Crop Assistance, and Biorefineries×8
Rural Development×8
Food and Drug Administration, and Related Agencies Appropriations Act×8
Agricultural Biorefinery Innovation and Opportunity×8
SUPPORT Act×8
Genetically Engineered×7
Prohibiting Adversarial Patents Act×7
Give Kids a Chance Act×7
Gene Editing×7
MCM PRV Program×7
American Innovation and R&D Competitiveness Act×7
Small Entity Update Act×7
Efficient Science-Based Review of Biotech Products×6
Bill to address patent thickets×6
Patent Eligibility Restoration Act×6
Sustainable Aviation Fuels Tax Credit×6
Tropical Disease Priority Review Voucher×6
Safe, and Secure American Bioeconomy×6
Pediatric Priority Review Voucher Program×6
Temporarily Refundable R&D Credit×6
HELP Copays Act×6
HHS Reorganization×6
Expanding Access to Capital Act×6
Most Favored Nation×6
Prescription Drug Price Relief Act×6
ASPR×6
Farm to Fly Act×5
Patent Thickets×5
Non-Opioid Analgesics×5
Administration Rebate Rule×5
Protected Classes×5
American Innovation Act×5
National Institute of Health×5
Orphan Drug Issues×5
BARDA×5
Farm Bill×4
International Consistency of Regulations×4
FY 2026 Appropriations Funding for Antimicrobial Resistance×4
FTC Orange Book Delisting Initiative×4
Protecting Americans Data from Foreign Adversaries Act×4
China Patent Reform×4
Biofuels and SAF×4
IRA Tax Credits×4
Decentralized Clinical Trials×4
FDA Hiring Flexibility Drug Importation Drug Manufacturing×4
VICP×4
Lower Costs×4
Executive Order on Achieving Efficiency Through State and Local Preparedness×4
340B Accountability Act×4
Fair Prescription Drug Prices for Americans Act×4
Creating Hope Reauthorization×4
Emerging New Threats and×4
Finding Orphan-Disease Remedies with Antifungal Research and Development×4
National Defense Authorization Act 2026×4
Food & Ag National Security×3
EPA proposed revisions to regulations×3
USMCA Review×3
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance×3
PTO Proposed Rules on Terminal Disclaimer Practice×3
Patent Litigation Reform×3
Reasonable Pricing Clauses in BARDA Contracts×3
Climate Change×3
House GOP RFI on Data Privacy×3
COVID-19 Lessons Learned×3
MCM PRV×3
Coverage and Reimbursement Orphan Drug Issues×3
Orphan Drug Tax Credit Pandemic Preparedness×3
Medical Countermeasures PRV Reauthorization×3
BSUFA Negotiations×3
Compounded Medicines Drug Patenting×3
Global Fairness in Drug Pricing Act×3
ETHIC Act×3
PPRV×3
Medicare Negotiation and Competitive Licensing Act×3
ASPR FY 2026 Appropriations for Specific Issues×3
China Synthetic Biotech Tariffs Trade Relations×3
Avian Flu×2
Office of Biopesticides and Pollution Prevention Division×2
Biotechnology and Agriculture Trade Program×2
Farm Bill Programs Energy Title IX×2
NextGen Aircraft Technology×2
Fuels & Metrics×2
Biomanufacturing and Jobs Act×2
Investment Tax Credit×2
Reasonable Pricing Clause Compulsory Licensing Data Privacy×2
Inventor Diversity for Economic Advancement×2
Orange Book Listing×2
World Health Organization×2
WHO Pandemic Preparedness Accord World Intellectual Property Office×2
Biomass Programs×2
340B Drug Discount Program×2
Biosecurity Infrastructure for Operational×2
NDAA×2
MINI Act×2
Medicaid Drug Rebate Program Rule×2
More Cures Act×2
Biodefense Research×2
Funding for Biodefense/Biomedical/Emergency Preparedness Research×2
Banking Policy×2
Putting Investors First Act×2
Infectious Disease Therapies Research and Innovation Act×2
Net Operating Loss Advance Refunds×2
Amended Definition of Smaller Reporting Company×2
Small Issuer Exemption Small Business Innovation Research×2
EU Ag-Biotech Policies×2
International Consistency of Regulation for Gene Edited Products×2
Korea Biotechnology Regulations×2
B5 Coalition on Supply Chain Resiliency×2
Cell & Gene Therapy×2
Most Favored Nation Foreign Drug Data Protection Laws×2
USDA×2
APHIS×2
Project Bio Shield×2
AMMTO×2
BETA×2
Funding for Biofuels×2
Improving Data Accessibility Through Advancements×2
Drug Evaluation and Review×2
Drug Importation Drug Manufacturing×2
Stronger Patents Act×2
Protecting Patient Access to Cancer and Therapies×2
More Transparency Act×2
VICP CICP×2
Family Vaccine Protection Act×2
R&D Payroll Credit×2
Net Operating Loss×2
Vaccines and Infectious Disease×2
US China IP Provisions×2
Dept of Commerce Patent Valuation Fee Proposal×2
National Institutes of Health FY 2026 Appropriations for Specific Issues×2
General Climate Change×1
Mexico Decree Banning Genetically Modified Corn Funding for the USDA×1
FY 2026 Appropriations Genetically Engineered×1
EPA Regulatory Approach to Gene Editing×1
FDA Proposed guidance on Gene Editing×1
USDA Regulatory Approach to Gene Editing Interagency Coordination×1
DOE and USDA Interagency Research Act×1
Regulatory Treatment of Gene Edited Products×1
Regulatory Treatment of Biostimulants United States-Mexico-Canada Agreement×1
Avian Flu Farm Bill×1
Funding for Antimicrobial Resistance×1
FY 2026 Appropriations Pandemic Preparedness×1
Bioenergy Technology Office×1
Environmental Energy R&D×1
Funding for Renewable Materials/Bio-based Products×1
Patentability of AI-Aided inventions Bayh-Dole Act/Tech Transfer×1
Invent Here×1
Make Here Act×1
March-In Rights×1
Title 35 to Address Infringements of Patents Claiming Biological Products×1
Protecting Consumer Access to Generic Drugs Act×1
USPTO Request for Comments: Experimental Use Defense 89 Fed×1
Reg 53963 Patenting of Biological Inventions×1
RESTORE Patent Rights Act×1
Fighting Climate Change through Biotechnology Innovation Funding for Biofuels×1
Mitigating Climate Change through Biotechnology Innovation Funding for Biofuels×1
Program & Oversight×1
American Pandemic Preparedness Plan×1
FY 2026 Appropriations Data Privacy×1
Clinical Trial Diversity Drug Evaluation and Review×1
CICP Funding for FDA×1
User Fees Funding for Health Resources and Services Administration×1
Funding for Womens Health Research International Reference Pricing Medicaid×1
Womens Health Research Pandemic Preparedness×1
General Cell & Gene Therapy×1
FY 2026 Appropriations Clinical Trial Data in China Data Privacy×1
General Diversity & Inclusion×1
Clinical Trial Diversity×1
General Drug Evaluation and Review×1
FY2025 Appropriations×1
PBN Reform×1
International Reference Pricing Foreign Drug Data Protection Laws×1
Regulatory Harmonization Funding for Antimicrobial Resistance×1
FY 2026 Appropriations International Reference Pricing Issues×1
Innovation and Pediatric Drugs Act×1
Impacting Emerging Companies×1
Regulatory Burden Capital Formation Incentives×1
JOBS Act 4.0×1
Market Liquidity Proposals×1
Public Float Threshold Update×1
SEC Small Business Forum×1
Small Business Capital Formation Enhancement Act×1
Mergers and Acquisitions Reform×1
Accredited Investor Certification Sarbanes Oxley Section 404×1
Adjusting the well-known seasoned issues×1
Definition to allow for a larger financing round using×1
General Pandemic Preparedness Renewable Chemicals/Bio-based Products×1
Tax Relief for American Families and Workers Act×1
R&D Payroll Credit Vaccine Injury Compensation Program×1
Medical Supply Chain Resiliency Act×1
Synthetic Biotech Pharmaceutical and Ag Biotech Tariffs US-China Trade Agreement×1
Ag-Biotech Provisions×1
IP Provisions World Health Organization×1
Patent Thickets Drug Pricing×1
Regulatory Harmonization Medicaid×1
Dept of Interior×1
Dept of Energy×1
Dept of Transportation×1
USDA Avian Flu×1
Foreign Animal Disease Efforts to expand the Bio Economy & Bio Manufacturing×1
Foreign Animal Disease Farm Bill×1
Department of Energy×1
Department of Transportation×1
USDA FY 2026 Appropriations for Specific Issues×1
Environment and Energy R&D×1
Renewable Materials/BIO-based Products×1
Renewable Chemicals/Bio-based Products Renewable Chemicals/Bio-based Products×1
March-In Rights Compulsory Licensing Data Privacy×1
Foreign Drug Data Protection Law×1
Efforts to expand the Bio Economy & Bio Manufacturing×1
BARDA FY 2026 Appropriations for Specific Issues×1
Section 317 Immunization Program 340B Drug Discount Program×1
Accelerated Approval Access to non-human Primates×1
Climate Change Data Privacy×1
PDUFA×1
FDA Reform×1
Compounding & Counterfeit Medicines Drug Patenting×1
Rare Disease Pilot Program Pandemic Preparedness×1
End Price Gauging for Medications Act×1
SMART Prices Act×1
HHS Reorganization Pandemic Preparedness×1
VICP Biofuels and SAF×1
Carbo Capture Utilization Parity Capital Formation Incentives×1
Counterfeit Drug Monitoring Drug Pricing×1
United Nations×1
US-China Ag-Biotech Provisions×1
World Trade Organization×1
Food and Ag Organization×1
Pharmacy Benefit Managers×1
General Artificial Intelligence×1
March-In Rights Data Privacy×1
Skinny Labels×1
Patent Tax/fees Foreign Drug Data Protection Law×1
National Institute of Health FY 2026 Appropriations for Specific Issues×1
Reimbursement Cell & Gene Therapy Data Privacy×1
Clinical Trial Modernization×1
Drug Rebate Program Rule×1
HHS Reorganization CDC Reform×1
Prescription Drug Pricing for the People Act×1
Capital Market Enhancements Small Business Innovation Research×1
Most Favored Nation Foreign Agricultural Biotechnology Laws and Regulations×1
Intellectual Property Enforcement×1
340B ACCESS Act×1
Synthetic Nucleic Acid Synthesis Screening×1
PDUFA VIII Negotiations×1
Drug Manufacturing×1
Biologics Competition Act×1
Enhanced Access to Affordable Medicines Act×1
Most Favored Nation Pricing Opioid Crisis×1
Reimbursement and Coverage of Innovative Products×1
Administrative Rebate Rule×1
MCM PRV Program CDC Reform×1
340B Rebate Pilot Program×1
FDA Hiring Flexibility Drug Manufacturing×1
Most Favored Nation Pricing×1
Vaccine Access×1
Vaccines for Children Program×1
Impacting Emerging Companies Capital Formation Incentives×1
Public Float Threshold Update Sarbanes Oxley Section 404×1
CMMI Models×1
Intellectual Property International Enforcement×1
Bilateral Trade Negotiations×1
Word Health Organization×1
Issue mix
LDA general-issue codes weighted by activity count.
Budget/Appropriations18
Copyright/Patent/Trademark18
Health Issues18
Homeland Security18
Medical/Disease Research/Clinical Labs18
Medicare/Medicaid18
Small Business18
Taxation/Internal Revenue Code18
Trade (domestic/foreign)18
Agriculture2